Company intelligence

Moonwalk Biosciences

Biotech
Last verified Sep 8, 2026

Key Metrics

Total funding
~$127M
As of Sep 8, 2026BioSpace

Recent changes

  1. Sep 8, 2026Raised $70M Series B BioSpace
  2. Sep 8, 2026First reported total funding: ~$127M BioSpace
  3. Sep 8, 2026New investor: Eli Lilly and Company BioSpace
  4. Sep 8, 2026New investor: ARCH Venture Partners BioSpace
  5. Sep 8, 2026New investor: Future Ventures BioSpace
Earlier changes (3)
  1. Sep 8, 2026New investor: Alpha Wave Global BioSpace
  2. Sep 8, 2026New investor: Khosla Ventures BioSpace
  3. Sep 8, 2026Moonwalk Biosciences Raises $70M For Obesity RNAi Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Sep 8, 2026Series B$70M—
Alpha Wave GlobalEli Lilly and CompanyARCH Venture PartnersKhosla VenturesFuture VenturesYK BioventuresGaorong Ventures
outlined = lead
BioSpace

Investors

Alpha Wave GlobalARCH Venture PartnersEli Lilly and CompanyFuture VenturesKhosla Ventures

Latest Pulse

  1. Moonwalk Biosciences Raises $70M For Obesity RNAiMoonwalk Biosciences closed an oversubscribed $70 million Series B to advance an adipose-targeted RNA interference therapy for obesity toward its first human trial, bringing total funding to roughly $127 million since its 2024 launch.→

Coverage Timeline

newest first
  1. FUNDINGMoonwalk Biosciences Raises $70M For Obesity RNAi→

All Coverage

FUNDING

Moonwalk Biosciences Raises $70M For Obesity RNAi

Related Companies

Shared investors
CognitionOpenAIPhysical IntelligenceRampOratomic
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction